Premium
Clinical implications of 2‐hydroxydesipramine plasma concentrations
Author(s) -
Nelson J Craig,
Bock Jay L,
Jatlow Peter I
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.28
Subject(s) - desipramine , clinical pharmacology , plasma concentration , metabolite , adverse effect , drug , depression (economics) , medicine , pharmacology , chemistry , antidepressant , macroeconomics , hippocampus , economics
The clinical utility of 2‐hydroxydesipramine (2‐OH‐DMI) measurements was evaluated by examining the relationship of 2‐OH‐DMI concentrations in plasma to clinical outcome and side effects in depressed inpatients treated with desipramine (DMI). Studies were performed in responders and nonresponders to treatment and in patients experiencing subjective side effects or major adverse reactions necessitating interruption of treatment. Unlike DMI concentrations, 2‐OH‐DMI concentrations did not correlate with response. Summing the concentrations of parent drug and metabolite (DMI + 2‐OH‐DMI) did not improve the correlation over that achieved with DMI alone. Neither DMI, 2‐OH‐DMI, nor their sum correlated with subjective side effect totals or major adverse reactions. While our data do not permit any conclusions regarding the clinical activity of 2‐OH‐DMI, they suggest that its routine measurement in plasma is not likely to be useful in the management of depression. Clinical Pharmacology and Therapeutics (1983) 33, 183–189; doi: 10.1038/clpt.1983.28